| Dr Tarek Khalife, MD | |
|
1025 Marsh St, Mankato, MN 56001-4752 | |
| (507) 625-4031 | |
| Not Available |
| Full Name | Dr Tarek Khalife |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 19 Years |
| Location | 1025 Marsh St, Mankato, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437388584 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 4301094081 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Health System - Mankato | Mankato, MN | Hospital |
| Mayo Clinic Health System-new Prague | New prague, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic Health System-southwest Minnesota Region | 4688585771 | 533 |
News Archive
A surgical team at the Peter Munk Cardiac Centre led by internationally-acclaimed cardiovascular surgeon, Dr. Vivek Rao, has successfully implanted a novel mechanical device, the HeartMate IIITM, into a patient with advanced heart failure.
Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.
More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.
Facing rising penalties under the health-care law for high readmission rates, some hospitals are turning to tech entrepreneurs like Chris Corio of San Francisco for help. Mr. Corio's four-year-old startup sells technology that assists patients in completing the recovery process after getting discharged.
The Wake Forest University Translational Science Institute (TSI) has announced a number of organizational changes. Four programs and four specialized centers have been organized to function collaboratively in support of research conducted at Wake Forest University Baptist Medical Center.
› Verified 2 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891701637 PECOS PAC ID: 4385556703 Enrollment ID: O20031104000408 |
News Archive
A surgical team at the Peter Munk Cardiac Centre led by internationally-acclaimed cardiovascular surgeon, Dr. Vivek Rao, has successfully implanted a novel mechanical device, the HeartMate IIITM, into a patient with advanced heart failure.
Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.
More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.
Facing rising penalties under the health-care law for high readmission rates, some hospitals are turning to tech entrepreneurs like Chris Corio of San Francisco for help. Mr. Corio's four-year-old startup sells technology that assists patients in completing the recovery process after getting discharged.
The Wake Forest University Translational Science Institute (TSI) has announced a number of organizational changes. Four programs and four specialized centers have been organized to function collaboratively in support of research conducted at Wake Forest University Baptist Medical Center.
› Verified 2 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545422 PECOS PAC ID: 4688585771 Enrollment ID: O20031110000134 |
News Archive
A surgical team at the Peter Munk Cardiac Centre led by internationally-acclaimed cardiovascular surgeon, Dr. Vivek Rao, has successfully implanted a novel mechanical device, the HeartMate IIITM, into a patient with advanced heart failure.
Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.
More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.
Facing rising penalties under the health-care law for high readmission rates, some hospitals are turning to tech entrepreneurs like Chris Corio of San Francisco for help. Mr. Corio's four-year-old startup sells technology that assists patients in completing the recovery process after getting discharged.
The Wake Forest University Translational Science Institute (TSI) has announced a number of organizational changes. Four programs and four specialized centers have been organized to function collaboratively in support of research conducted at Wake Forest University Baptist Medical Center.
› Verified 2 days ago
| Entity Name | Mayo Clinic Health System-fairmont |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366410862 PECOS PAC ID: 4981694981 Enrollment ID: O20040719000142 |
News Archive
A surgical team at the Peter Munk Cardiac Centre led by internationally-acclaimed cardiovascular surgeon, Dr. Vivek Rao, has successfully implanted a novel mechanical device, the HeartMate IIITM, into a patient with advanced heart failure.
Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.
More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.
Facing rising penalties under the health-care law for high readmission rates, some hospitals are turning to tech entrepreneurs like Chris Corio of San Francisco for help. Mr. Corio's four-year-old startup sells technology that assists patients in completing the recovery process after getting discharged.
The Wake Forest University Translational Science Institute (TSI) has announced a number of organizational changes. Four programs and four specialized centers have been organized to function collaboratively in support of research conducted at Wake Forest University Baptist Medical Center.
› Verified 2 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1124035282 PECOS PAC ID: 4688585771 Enrollment ID: O20171011003939 |
News Archive
A surgical team at the Peter Munk Cardiac Centre led by internationally-acclaimed cardiovascular surgeon, Dr. Vivek Rao, has successfully implanted a novel mechanical device, the HeartMate IIITM, into a patient with advanced heart failure.
Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.
More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.
Facing rising penalties under the health-care law for high readmission rates, some hospitals are turning to tech entrepreneurs like Chris Corio of San Francisco for help. Mr. Corio's four-year-old startup sells technology that assists patients in completing the recovery process after getting discharged.
The Wake Forest University Translational Science Institute (TSI) has announced a number of organizational changes. Four programs and four specialized centers have been organized to function collaboratively in support of research conducted at Wake Forest University Baptist Medical Center.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tarek Khalife, MD N10561 Grandview Ln, Aspirus Grand View Hospital, Ironwood, MI 49938-9622 Ph: (906) 932-6215 | Dr Tarek Khalife, MD 1025 Marsh St, Mankato, MN 56001-4752 Ph: (507) 625-4031 |
News Archive
A surgical team at the Peter Munk Cardiac Centre led by internationally-acclaimed cardiovascular surgeon, Dr. Vivek Rao, has successfully implanted a novel mechanical device, the HeartMate IIITM, into a patient with advanced heart failure.
Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.
More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.
Facing rising penalties under the health-care law for high readmission rates, some hospitals are turning to tech entrepreneurs like Chris Corio of San Francisco for help. Mr. Corio's four-year-old startup sells technology that assists patients in completing the recovery process after getting discharged.
The Wake Forest University Translational Science Institute (TSI) has announced a number of organizational changes. Four programs and four specialized centers have been organized to function collaboratively in support of research conducted at Wake Forest University Baptist Medical Center.
› Verified 2 days ago
Stephen D Penkhus, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1230 E Main St, Mankato, MN 56002 Phone: 507-625-1811 | |
Tara Jean Denke, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1230 E Main Street, Mankato Clinic At Main Street, Mankato, MN 56002 Phone: 507-625-1811 | |
Dr. Salvador Javier Cardenas, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1025 Marsh St, Mankato, MN 56001 Phone: 507-790-7070 | |
Dr. Scott J Barnacle, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1230 E Main Street, Mankato, MN 56002 Phone: 507-625-1811 | |
Dr. Heather R Carlson, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1230 E. Main Street, Mankato Clinic At Main Street, Mankato, MN 56002 Phone: 507-625-1811 | |
Dr. Amy L. Brien, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1015 Marsh St, Mankato, MN 56001 Phone: 507-385-4842 |